{"id":"NCT04350606","sponsor":"Pfizer","briefTitle":"A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia","officialTitle":"A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF PF-06462700 ADMINISTERED INTRAVENOUSLY AT 40 MG/KG/DAY FOR 4 DAYS IN JAPANESE PARTICIPANTS WITH MODERATE AND ABOVE APLASTIC ANEMIA","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-07-25","primaryCompletion":"2021-01-22","completion":"2021-04-19","firstPosted":"2020-04-17","resultsPosted":"2022-04-27","lastUpdate":"2022-04-27"},"enrollment":3,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Aplastic Anemia"],"interventions":[{"type":"BIOLOGICAL","name":"PF-06462700","otherNames":["Brand name in the US: ATGAM"]}],"arms":[{"label":"PF-006462700 group","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess the efficacy and safety of PF-06462700 administered intravenously at 40 mg/kg/day for 4 days in Japanese participants with moderate and above aplastic anemia for making an approval application in Japan.","primaryOutcome":{"measure":"Number of Participants With Hematologic Response at Week 12","timeFrame":"Week 12 Follow-up Visit","effectByArm":[{"arm":"PF-06462700","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":16},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":["36441357"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=B5411003"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":3},"commonTop":["Abdominal pain","Nausea","Hyperglycaemia","Hypertension","Adrenal insufficiency"]}}